MiMedx Group, Inc., a leading developer and marketer of regenerative and therapeutic biologics, announced that it has appointed Mark P. Graves to the position of Chief Compliance Officer.  Mr. Graves will be responsible for providing direction and oversight of MiMedx's compliance program, including the Company's regulatory and legal compliance matters related to the Company's risk management, sales operations and financial reporting. Mr. Graves will report to Ed Borkowski, the Company's Executive Vice President and Interim Chief Financial Offficer on a day-to-day basis. He will also report directly to the newly formed Ethics and Compliance Committee of the Board of Directors.

"We are implementing plans to improve our corporate compliance practices in order to ensure our Company adheres to policies with the highest integrity, ethics and legal standards," said David Coles, interim Chief Executive Officer, MiMedx. "Mark has a strong background in driving compliance strategy, risk awareness, training, and crafting effective policy. He will help MiMedx apply and execute on best-in-class compliance standards that reflect our commitment to enhancing value for all stakeholders. We are pleased to welcome him to our organization."

Graves brings more than 20 years of pharmaceutical and biotech industry experience to MiMedx, ranging from compliance and sales management to government affairs. He most recently was the U.S. leader for the global Patient Experience & Value function in the neurology division of UCB, Inc., a biopharmaceutical company. From 2011 to 2015, he was UCB's Deputy Compliance Officer involved in all aspects of compliance, including the implementation and management of the company's corporate integrity agreement. Prior to that, Graves was Senior Director in the Office of Ethics and Compliance for the Pharmaceutical Products Division of Abbott Laboratories, as well as Deputy Ethics & Compliance Officer for Takeda Pharmaceuticals North America, Inc. and TAP Pharmaceutical Products, Inc. Prior to his pharmaceutical and biotech career, he practiced labor and employment law.

Graves holds a B.A. in Criminology and Law, and a J.D. from the University of Florida as well as an MBA from the University of Chicago Booth School of Business.

The Audit Committee and the Company are developing and implementing corrective measures to improve MiMedx's accounting and internal control practices. As part of this initiative, and as noted in the Company's June 7, 2018 press release, the MiMedx Board of Directors established an Ethics and Compliance Committee, which includes independent directors Luis A. Aguilar and Neil S. Yeston M.D. The Company also is conducting a formal search to fill the newly established positions of Chief Accounting Officer and Internal Auditor.